These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24468524)

  • 1. Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens.
    Väänänen RM; Lilja H; Kauko L; Helo P; Kekki H; Cronin AM; Vickers AJ; Nurmi M; Alanen K; Bjartell A; Pettersson K
    Urology; 2014 Feb; 83(2):511.e1-7. PubMed ID: 24468524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates.
    Väänänen RM; Ochoa NT; Boström PJ; Taimen P; Pettersson K
    BMC Urol; 2015 Aug; 15():88. PubMed ID: 26294063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PCA3 AND TMPRSS2:ERG GENES EXPRESSION IN BIOPSIES OF BENIGN PROSTATE HYPERPLASIA, INTRAEPITHELIAL NEOPLASIA, AND PROSTATE CANCER].
    Mikhaylenko DS; Perepechin DV; Grigoryeva MV; Zhinzhilo TA; Safronova NY; Efremov GD; Sivkov AV
    Urologiia; 2015; (5):46-50. PubMed ID: 26859937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men.
    Koide H; Kimura T; Inaba H; Sato S; Iwatani K; Yorozu T; Furusato B; Kamata Y; Miki J; Kiyota H; Takahashi H; Egawa S
    Prostate; 2019 Jan; 79(1):3-8. PubMed ID: 30051483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
    Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
    Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
    Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
    Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.
    Whelan C; Kawachi M; Smith DD; Linehan J; Babilonia G; Mejia R; Wilson T; Smith SS
    J Urol; 2014 Jan; 191(1):220-6. PubMed ID: 23669563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
    Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
    Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
    Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
    Alinezhad S; Väänänen RM; Ochoa NT; Vertosick EA; Bjartell A; Boström PJ; Taimen P; Pettersson K
    BMC Urol; 2016 Feb; 16():10. PubMed ID: 26928323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics.
    Mytsyk Y; Nakonechnyi Y; Dosenko V; Kowal P; Pietrus M; Gazdikova K; Labudova M; Caprnda M; Prosecky R; Dragasek J; Kruzliak P; Dats R
    Clin Biochem; 2023 Jun; 116():120-127. PubMed ID: 37121562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
    Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
    Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
    Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens.
    Väänänen RM; Lilja H; Cronin A; Kauko L; Rissanen M; Kauko O; Kekki H; Vidbäck S; Nurmi M; Alanen K; Pettersson K
    Clin Biochem; 2013 May; 46(7-8):670-4. PubMed ID: 23391636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.
    Brooks JD; Wei W; Hawley S; Auman H; Newcomb L; Boyer H; Fazli L; Simko J; Hurtado-Coll A; Troyer DA; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; McKenney JK
    PLoS One; 2015; 10(7):e0132343. PubMed ID: 26172920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
    Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
    Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells.
    Lippolis G; Edsjö A; Stenman UH; Bjartell A
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):145-50. PubMed ID: 23459095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
    Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
    Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue.
    Alinezhad S; Väänänen RM; Tallgrén T; Perez IM; Jambor I; Aronen H; Kähkönen E; Ettala O; Syvänen K; Nees M; Kallajoki M; Taimen P; Boström PJ; Pettersson K
    Urol Oncol; 2016 Jun; 34(6):255.e15-22. PubMed ID: 26857646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.